

Indivior PLC

Notice of Annual General Meeting

Wednesday, May 8, 2019 at 11.00am

At the offices of Addleshaw Goddard LLP, Milton Gate,
60 Chiswell Street, London EC1Y 4AG

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the action to be taken, you should immediately consult your stockbroker, solicitor, accountant or other independent advisor who, if you are taking advice in the United Kingdom, is duly authorized under the Financial Services and Markets Act 2000, or an appropriately authorized independent advisor if you are in a territory outside the United Kingdom. If you have recently sold or transferred all of your shares in Indivior PLC, please forward this document, together with the accompanying documents (but not the personalized form of proxy), as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares. If you have sold or otherwise transferred only part of your holding, you should retain this document and its enclosures.

Notice of Annual General Meeting

Dear Shareholder,

I am pleased to enclose the Notice of Meeting for the Annual General Meeting ('AGM') of the Company. The AGM is to be held on Wednesday, May 8, 2019 at 11.00am at the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London EC1Y 4AG.

The formal notice of AGM and resolutions to be proposed are set out on pages 3 to 4 of this document. Explanatory notes to the business to be considered are set out on pages 5 to 9.

The business of this year's meeting comprises resolutions that are regularly brought to shareholders of public companies.

Action to be taken

We encourage you to attend the AGM, for an opportunity to communicate with the Directors and to vote on the proposed resolutions. Your votes are important to us. Further information regarding the ways in which you can vote is given in the Notes on pages 10 to 12. Should you be unable to attend the AGM in person, you can appoint another person as your proxy to exercise all or any of your rights to attend, vote and speak at the meeting. Details of how to do this are included in the Notes on pages 10 to 12. To be valid, the proxy appointment must be received at the address for delivery specified in the Notes by no later than 11.00am on Friday May 3, 2019.

Recommendation

The Directors consider that each of the proposed resolutions set out in the notice of AGM is in the best interests of the Company and its shareholders and most likely to promote the success of the Company for the benefit of members as a whole. Accordingly, my fellow Directors and I unanimously recommend that shareholders vote in favor of those resolutions, as we each intend to do in respect of our own beneficial shareholdings in the Company (save in respect of those resolutions in which we are interested).

Yours faithfully,


Howard Pien Chair

Indivior PLC, 103–105 Bath Road
Slough, Berkshire, SL1 3UH

Company registration number: 09237894

March 14, 2019

Location of AGM



At the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London EC1Y 4AG

Transportation

By underground: Moorgate, Barbican or Liverpool Street

By train: Moorgate or Liverpool Street

By bus: 21, 43, 76, 100, 141, 153, 214, 271 or 388

By car: Barbican Centre, Beech Street/Silk Street EC2Y 8DS

Up to date travel information can be obtained from Transport for London at www.tfl.gov.uk (tel: 0343 2221234)

Notice is hereby given that the Annual General Meeting of Indivior PLC ('Indivior' or the 'Company') will be held on Wednesday, May 8, 2019 at 11.00 am at the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London EC1Y 4AG, to transact the following business.

Resolutions 1 to 16 will be proposed as Ordinary Resolutions and Resolutions 17 to 20 will be proposed as Special Resolutions. Voting on all resolutions will be by way of a poll.

Report and Accounts

1. To receive the Company's audited accounts and the reports of the Directors and the Auditor for the year ended December 31, 2018.

Directors' Remuneration Report

2. To approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy which was approved at the 2018 AGM) set out in the Annual Report and Accounts for the year ended December 31, 2018.

Directors

3. To re-appoint Howard Pien as a Director.
4. To re-appoint Shaun Thaxter as a Director.
5. To re-appoint Mark Crossley as a Director.
6. To re-appoint Dr A. Thomas McLellan as a Director.
7. To re-appoint Tatjana May as a Director.
8. To re-appoint Lorna Parker as a Director.
9. To re-appoint Daniel J. Phelan as a Director.
10. To re-appoint Christian Schade as a Director.
11. To re-appoint Daniel Tassé as a Director.
12. To re-appoint Lizabeth Zlatkus as a Director.

Re-appointment of Auditor

13. To re-appoint PricewaterhouseCoopers LLP as Auditor of the Company to hold office until the conclusion of the next general meeting of the Company at which the accounts are laid before the Company.
14. To authorize the Audit Committee of the Board to determine the remuneration of the Auditor.

Political donations and political expenditure

15. To authorize the Company and any UK registered company which is or becomes a subsidiary of the Company during the period to which this resolution relates and in accordance with sections 366 and 367 of the Companies Act 2006 to:
 - (a) make political donations to political parties or independent election candidates, or both, up to a total aggregate amount of £50,000;
 - (b) make political donations to political organizations other than political parties up to a total aggregate amount of £50,000; and
 - (c) incur political expenditure up to a total aggregate amount of £50,000

as such terms are defined in Part 14 of the Companies Act 2006 during the period beginning on the date of the passing of this resolution and ending on the date of the Company's next AGM, provided that the aggregate expenditure under paragraphs (a), (b) and (c) shall not exceed £50,000 in total. The authorized sum referred to in paragraphs (a), (b) and (c) above may be comprised of one or more amounts in different currencies which, for the purposes of calculating the said sum, shall be converted into Pounds Sterling at the exchange rate published in the London edition of the Financial Times on the day on which the relevant donation is made or expenditure incurred or, if earlier, on the day on which the Company enters into any contract or undertaking in relation to the same (or, if the relevant day is not a business day, the first business day thereafter).

Directors' authority to allot shares

16. THAT the Directors pursuant to and in accordance with section 551 of the Companies Act 2006, in substitution for all existing authorities vested in the Directors on the date of the notice of this meeting to the extent they remain unexercised at the commencement of this meeting, are generally and unconditionally authorized to exercise all the powers of the Company to allot shares in the Company and grant rights to subscribe for, or to convert any security into, shares in the Company:
 - (a) up to an aggregate nominal amount of US\$24,334,352; and
 - (b) up to a further aggregate nominal amount of US\$24,334,352 provided that (i) they are equity securities (as defined in section 560(1) of the Companies Act 2006), and (ii) they are offered in connection with an offer by way of a rights issue to holders of ordinary shares on the register of members at such record date as the Directors may determine where the equity securities respectively attributable to the interests of the ordinary shareholders are proportionate (as nearly as may be practicable) to the respective numbers of ordinary shares held or deemed to be held by them on any such record date and to other holders of equity securities entitled to participate therein

subject to any limits or restrictions or arrangements the Directors may impose which they consider necessary or appropriate to deal with Treasury shares, fractional entitlements, record dates, legal, regulatory, or practical problems in, or laws of, any territory, the requirements of any stock exchange or by virtue of shares being represented by depositary receipts, or any matter, such authority to apply until the end of next year's AGM (or, if earlier, until the close of business on June 30, 2020) but during this period the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted and rights to subscribe for, or to convert securities into, shares in the Company to be granted after the authority ends and the Directors may allot equity securities and grant rights under any such offer or agreement as if the authority had not expired.

Disapplication of pre-emption rights

17. THAT, subject to the passing of Resolution 16 above and in substitution for all existing powers vested in the Directors on the date of the notice of this meeting to the extent they remain unexercised at the commencement of this meeting, the Directors are empowered pursuant to section 570 and section 573 of the Companies Act 2006 to allot equity securities (within the meaning of section 560 of the Companies Act 2006) wholly for cash pursuant to the authority conferred by Resolution 16 or by way of sale of Treasury shares as if section 561(1) of the Companies Act 2006 did not apply to any such allotment, provided that this power shall be limited:

- (a) to the allotment of equity securities (but in the case of the authority granted under paragraph (b) of Resolution 16 by way of rights issue only) and sale of Treasury shares for cash in connection with an offer of, or invitation to apply for, equity securities to shareholders in proportion (as nearly as may be practicable) to their existing holdings and that the Directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with Treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory, the requirements of any stock exchange or by virtue of shares being represented by depositary receipts, or any other matter; and
- (b) to the allotment of equity securities and sale of Treasury shares (otherwise than under paragraph (a) above) up to an aggregate nominal amount of US\$3,650,152

such power to apply until the end of next year's AGM (or, if earlier, until the close of business on June 30, 2020) but during this period the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and Treasury shares to be sold) after the power ends and the Directors may allot equity securities and sell Treasury shares under any such offer or agreement as if the power had not expired.

18. THAT, subject to the passing of Resolution 16 above, the Directors are empowered pursuant to section 570 and section 573 of the Companies Act 2006 in addition to any power granted under Resolution 17 above to allot equity securities (within the meaning of section 560 of the Companies Act 2006) wholly for cash pursuant to the authority conferred by Resolution 16 or by way of sale of Treasury shares as if section 561(1) of the Companies Act 2006 did not apply to any such allotment, provided that this power shall be:

- (a) limited to the allotment of equity securities or sale of Treasury shares up to an aggregate nominal amount of US\$3,650,152; and
- (b) used only for the purpose of financing (or refinancing, if the power is to be used within six months after the original transaction) a transaction which the Directors determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-emption Rights most recently published by the Pre-emption Group prior to the date of this notice,

such power to apply until the end of next year's AGM (or, if earlier, until the close of business on June 30, 2020) but during this period the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and Treasury shares to be sold) after the power ends and the Directors may allot equity securities and sell Treasury shares under any such offer or agreement as if the power had not expired.

Authority to purchase own shares

19. THAT the Company is generally and unconditionally authorized for the purpose of section 701 of the Companies Act 2006 to make market purchases (as defined in section 693(4) of that Act) of ordinary shares in the capital of the Company, provided that:

- (a) the maximum number of ordinary shares that may be purchased is 73,003,058;
- (b) the minimum price that may be paid for an ordinary share shall be not less than the nominal value of such share;
- (c) the maximum price to be paid for each ordinary share shall be the higher of (i) an amount equal to 5% above the average of the middle market quotation for the Company's ordinary shares as derived from the London Stock Exchange's Official List for the five business days prior to the purchase being made and (ii) the higher of the price of the last independent trade and the highest current independent bid for an ordinary share on the London Stock Exchange at the time the purchase is carried out;
- (d) this authority will expire on the earlier of the close of business on June 30, 2020 or the conclusion of the Company's AGM in 2020, unless such authority is previously renewed, varied or revoked by the Company in a general meeting; and
- (e) the Company may enter into a contract to purchase its ordinary shares under this authority prior to its expiry, which will or may be executed wholly or partly after such expiry.

Notice of general meetings

20. THAT a general meeting of the Company other than an annual general meeting may be called on not less than 14 clear days' notice.

By order of the Board

Kathryn Hudson
Company Secretary

Indivior PLC
103-105 Bath Road
Slough, Berkshire, SL1 3UH

Company registration number: 09237894

March 14, 2019

Notes to the Resolutions

Notes to the Resolutions

Resolutions 1 to 16 are to be proposed as Ordinary Resolutions. This means that for each of those resolutions to be passed, more than half of the total voting rights of members who (being entitled to do so) vote must be in favor of the resolution. Resolutions 17 to 20 are to be proposed as Special Resolutions. This means that for each of those resolutions to be passed, not less than three-quarters of the total voting rights of members who (being entitled to do so) vote must be in favor of the resolution.

An explanation for each resolution is set out below.

Ordinary Resolutions

Resolution 1 – Report and Accounts

Resolution 1 asks shareholders to receive the Company's reports and accounts for the financial year which ended on December 31, 2018. These include both the consolidated accounts and Indivior's stand-alone accounts, together with the strategic report and the other reports of the Directors and of the Auditor. These are all contained in the Annual Report and Accounts 2018.

Resolution 2 – Directors' Remuneration Report

Resolution 2 seeks shareholder approval of the Directors' Remuneration Report, other than the part containing the Directors' Remuneration Policy. This resolution is advisory in nature, meaning that payments and benefits made or promised to Directors would not have to be repaid or withheld should the resolution not be passed. The Directors' Remuneration Report can be found on pages 62 to 77 of the Annual Report and Accounts 2018 and gives details of the Directors' remuneration for the year ended December 31, 2018. The Company's Auditor, PricewaterhouseCoopers LLP, has audited those parts of the Directors' Remuneration Report that are required to be audited and their report can be found on pages 85 to 94 of the Annual Report and Accounts 2018.

The Companies Act 2006 requires the Directors' Remuneration Policy to be put to shareholders for approval annually unless the policy remains unchanged, in which case it need only be put to shareholders for approval at least every three years. The Company is not proposing any changes to the Directors' Remuneration Policy approved at the AGM in 2018.

Resolutions 3 to 12 – Re-appointment of Directors

Resolutions 3 to 12 are to re-appoint each of the Directors of the Board who have held office from the date of the last AGM, with the exception of Dr Yvonne Greenstreet, who is not seeking re-appointment. The 2018 UK Corporate Governance Code recommends that all directors should be subject to annual re-appointment by shareholders. The Board has agreed that all Directors (other than Dr Greenstreet) will, therefore, be subject to re-appointment at the 2019 AGM.

Following the formal performance evaluation of each Director, which was undertaken in 2018, the Chair has confirmed that each of the Directors who are seeking re-appointment have been and continue to be effective members of the Board and demonstrate commitment to their role and responsibilities. Daniel Tassé was appointed CEO of DBV Technologies SA in November 2018 and has a transition plan to reduce his other commitments during the course of 2019, so that he will serve on two boards (including Indivior PLC) in a non-executive capacity in addition to his

executive role. The Board has considered Mr Tassé's other commitments and as a result of his plan to reduce his commitments does not consider that he is overboarded. The Board are satisfied that Mr Tassé devotes sufficient time to effectively discharge his duties. As such, the Board recommends the re-appointment of each Director standing for re-appointment.

Resolution 3

Howard Pien

Chair

Skills and experience

- ◀ Howard has more than 30 years of pharmaceutical and biotechnology industry experience and brings strong and decisive leadership to the Board
- ◀ Vanda Pharmaceuticals, Inc.: Non-Executive Chairman (2010-2016)
- ◀ GlaxoSmithKline: various Executive positions (1991-2003)
- ◀ Chiron, Corp: President and CEO (2003-2006) and later Chairman of the Board (2004-2006)
- ◀ Medarex Inc.: CEO and President (2007-2009)
- ◀ Abbott Laboratories and Merck & Co.: Product Manager, Business Unit Director, cardiovasculars, anti-infectives (1986-1991)
- ◀ Juno Therapeutics: Non-executive Chairman (2014-2018)

Other current appointments

- ◀ Idera Pharmaceuticals, Inc.: Director
- ◀ Sapience Therapeutics: Chairman

Board Committees: None

Resolution 4

Shaun Thaxter

Chief Executive Officer

Skills and experience

- ◀ Shaun has more than 25 years of pharmaceutical and prescription products industry experience. He is responsible for executing Indivior's strategy and leading the management team
- ◀ Appointed CEO of Indivior at time of Reckitt Benckiser Pharmaceuticals demerger
- ◀ Institute of Directors (IoD): Chartered Director and Fellow
- ◀ National Association of Corporate Directors (NACD): Board Leadership Fellow
- ◀ Reckitt Benckiser Pharmaceuticals, Inc.: President
- ◀ Reckitt Benckiser: Global Category Manager

Other current appointments: None

Board Committees: None

Notes to the Resolutions continued

Resolution 5

[Mark Crossley](#)

Chief Financial Officer

Skills and experience

- ◁ Mark has a wealth of financial and pharmaceutical industry experience and knowledge
- ◁ Indivior Chief Strategy Officer
- ◁ Reckitt Benckiser Pharmaceuticals Inc.: Global Finance Director
- ◁ Procter and Gamble: Associate Director Corporate Portfolio Finance
- ◁ Procter and Gamble: Associate Director Female Beauty Strategy and Business Planning
- ◁ National Association of Corporate Directors (NACD): Board Leadership Fellow

Other current appointments: None

Board Committees: None

Resolution 6

[A. Thomas McLellan, PhD](#)

Independent Non-Executive Director

Skills and experience:

- ◁ Tom's extensive experience in the field of addictions spans more than 35 years as a career researcher in the treatment of and policy-making around substance use and abuse. This enables him to contribute valuable insight and perspective to his work on Indivior's Science & Policy Committee
- ◁ Published more than 450 articles and chapters on addiction research
- ◁ Treatment Research Institute (TRI): Co-founder, CEO and Chairman until September 1, 2016
- ◁ White House Office of National Drug Control Policy (2009-11): Deputy Director

Other current appointments:

- ◁ Recover Together, Inc.: Director
- ◁ Serves on several editorial boards of scientific journals

Board Committees:

- ◁ Nomination & Governance Committee
- ◁ Science & Policy Committee

Resolution 7

[Tatjana May](#)

Independent Non-Executive Director

Skills and experience:

- ◁ Tatjana combines substantial knowledge and understanding of the pharmaceutical sector with more than 20 years of legal experience and brings both UK and US listed company expertise to Board discussions
- ◁ Shire plc: General Counsel and Company Secretary, Executive Committee Member (2001 – 2015)
- ◁ Astra Zeneca plc: various positions including Assistant General Counsel (1995 – 2001)
- ◁ Slaughter and May: Lawyer (1988-1994)

Other current appointments:

- ◁ EIP Inc; Non-Executive Director
- ◁ National Youth Orchestra of Great Britain: Trustee

Board Committees:

- ◁ Nomination & Governance Committee
- ◁ Remuneration Committee

Resolution 8

[Lorna Parker](#)

Independent Non-Executive Director

Skills and experience:

- ◁ With more than 25 years of executive search, management assessment and board consulting experience, and UK listed company experience, Lorna provides strong leadership on governance matters including succession planning
- ◁ Conducts board effectiveness reviews for FTSE 100 companies
- ◁ Spencer Stuart: Partner (1989-2008); led the private equity practice across Europe and the legal search practice globally
- ◁ BC Partners: Senior Advisor (2008-2016)
- ◁ Future Academies: Director (2014-2017)

Other current appointments:

- ◁ CVC Capital Partners: Senior Advisor
- ◁ Manchester Square Partners: Senior Advisor
- ◁ Royal Horticultural Society: Trustee
- ◁ National Opera Studio: Trustee

Board Committees:

- ◁ Nomination & Governance Committee (Chair)
- ◁ Remuneration Committee

Resolution 9

[Daniel J. Phelan](#)

Independent Non-Executive Director

Skills and experience:

- ◁ Dan possesses more than 30 years of pharmaceutical and executive management experience, including extensive experience dealing with executive remuneration matters. He is an active and knowledgeable Chair of the Remuneration Committee and provides valuable perspective to the work of the Nomination & Governance Committee
- ◁ GlaxoSmithKline: Advisor to three CEOs and various executive positions (1981-2012)
- ◁ Computer Sciences Corporation: Advisory Board member (2013-2015)
- ◁ RiseSmart: Advisory Board member (2012-2016)
- ◁ Rutgers University Board of Trustees: Member (2013-2017)

Other current appointments:

- ◁ TE Connectivity Ltd: Board Director

Board Committees:

- ◁ Remuneration Committee (Chair)
- ◁ Nomination & Governance Committee

Resolution 10

[Christian Schade](#)

Independent Non-Executive Director

Skills and experience:

- ◁ Chris's significant pharmaceutical and financial industry experience gained over more than 20 years in US listed companies make him a strong Chair of the Audit Committee, able to challenge incisively the Group's financial performance and approach to risk management
- ◁ Novira Therapeutics, Inc.: CEO (2014-2015)
- ◁ Omthera Pharmaceuticals, Inc.: CFO, EVP (2011-2013)
- ◁ NRG Energy, Inc.: CFO, EVP (2010-2011)
- ◁ Medarex Inc.: CFO, SVP (2000-2009)
- ◁ Merrill Lynch & Co.: MD, Debt Capital Markets (1992-2000)

Other current appointments:

- ◁ Aprea Therapeutics AB: President & Chief Executive Officer
- ◁ Integra LifeSciences Holdings Corporation: Director
- ◁ Sapience Therapeutics: Director

Board Committees:

- ◁ Audit Committee (Chair)
- ◁ Science & Policy Committee

Resolution 11

[Daniel Tassé](#)

Senior Independent Director

Skills and experience:

- ◁ Daniel has a strong track record of leading global organizations with more than 35 years of pharmaceutical and financial industry experience. He is an effective Senior Independent Director with a balanced understanding of the concerns of major shareholders
- ◁ Ikaria Holdings, Inc.: CEO and President (2008-2015), Chairman (2009-2015)
- ◁ Baxter International: General Manager of Pharmaceuticals and Technologies Business Unit
- ◁ GlaxoSmithKline: various senior management positions including President and Regional Director for Australasia (2001-2004)

Other current appointments:

- ◁ DBV Technologies SA: CEO
- ◁ Bellerophon Therapeutics: Director
- ◁ HLS Therapeutics Inc.: Director
- ◁ REGENXBIO Inc.: Director

Board Committees:

- ◁ Audit Committee
- ◁ Remuneration Committee

Resolution 12

[Lizabets Zlatkus](#)

Independent Non-Executive Director

Skills and experience

- ◁ Liz is a financial and risk expert with significant audit and risk experience gained in both UK and US listed organizations. Her financial skills and knowledge are valuable to the work of the Audit Committee in particular
- ◁ The Hartford: various senior executive positions (1996-2011)
- ◁ Audit, Risk, Compensation and Nomination Committee experience
- ◁ Legal & General: Non-Executive Director (2013-2016)
- ◁ Computer Sciences Corporation (2016-2017)

Other current appointments:

- ◁ Boston Private Financial Holdings: Non-Executive Director
- ◁ SE2: Board member
- ◁ Connecticut Science Center: Board of Trustees, Vice Chair
- ◁ Axis Capital Holdings Limited: Director

Board Committees:

- ◁ Audit Committee
- ◁ Science & Policy Committee

Resolutions 13 to 14 – Auditor

The Company is required to appoint an auditor at each general meeting at which accounts are presented, to hold office until the end of the next meeting of that type.

The Audit Committee has recommended to the Board the re-appointment of the Company's existing Auditor, PricewaterhouseCoopers LLP. The Audit Committee has confirmed that its recommendation is free from third party influence and that no restrictive contractual provisions have been imposed on the Company limiting the choice of auditor.

Accordingly, the Board proposes as Resolution 13 an ordinary resolution to re-appoint PricewaterhouseCoopers LLP as the Auditor.

Resolution 14 follows best practice in corporate governance by separately seeking authority for the Audit Committee to determine the Auditor's remuneration.

Resolution 15 – Political donations

Resolution 15 deals with the rules on political donations and expenditure contained in the Companies Act 2006. The definition of political donations and expenditure in this context is very wide and extends to donations and expenditure incurred in relation to bodies or activities concerned with policy review, law reform and the representation of the business community. It could also include special interest groups, such as those involved with the environment even though these activities are not designed to support or influence support for a particular political party. Whilst the Company and its UK subsidiaries do not intend to make donations to political parties, political organizations or to independent election candidates, within the normal meaning of that expression, the Directors consider that it is in the best interests of the shareholders for the Company to participate in public debate and opinion-forming on matters which affect its business. To avoid inadvertently infringing the Companies Act 2006, the Directors are seeking authority for the Company and its UK subsidiaries to make political donations and to incur political expenditure during the period from the date of the AGM in 2019 to the end of the AGM in 2020 up to an aggregate amount of £50,000.

It is worth noting, however, that the Company's US subsidiaries do make political donations as defined under UK law. Donations by the Company's US subsidiaries are not permitted to exceed US\$500,000.

Resolution 16 – Directors' authority to allot shares

Resolution 16 seeks authority under the Companies Act 2006 for Directors to allot ordinary shares in the capital of the Company. The Directors' existing allotment authority is due to expire at the 2019 AGM. The UK Investment Association ('IA') guidelines on Directors' authority to allot shares state that IA members will regard as routine resolutions seeking authority to allot shares representing up to two-thirds of the Company's issued share capital, provided that any amount in excess of one-third of the Company's issued share capital is only used to allot shares pursuant to a fully pre-emptive rights issue.

In light of these guidelines, the Board considers it appropriate that Directors be granted authority to allot shares in the capital of the Company up to a maximum nominal amount of US\$48,668,704 representing two-thirds or

approximately 67% of the Company's issued ordinary share capital as at February 28, 2019 (the latest practicable date prior to publication of this document).

Of this amount, a nominal amount of US\$24,334,352 (representing one-third or approximately 33% of the Company's issued ordinary share capital) can only be allotted pursuant to a rights issue. The authority will last until the end of the AGM in 2020 or, if earlier, until the close of business on June 30, 2020. The Directors have no present intention to allot new ordinary shares other than to fulfil the Company's obligations under its executive and employee share plans. As at February 28, 2019 the Company held no ordinary shares in Treasury.

Special Resolutions

Resolutions 17 to 18 – Disapplication of pre-emption rights

Resolutions 17 and 18 will, if passed, authorize the Directors to allot equity securities, or to sell any securities out of Treasury, for cash, without first offering those securities to existing holders in proportion to their existing holdings. The proposed resolutions essentially replicate the powers which were granted at last year's AGM (and which will expire at the 2019 AGM).

Resolution 17 is to be proposed as a special resolution. As in previous years, if this resolution is passed by shareholders, it will permit the Directors to allot:

- (a) equity securities up to a nominal amount of US\$48,668,704 (representing two-thirds of the Company's issued share capital as at February 28, 2019 (the latest practicable date prior to the publication of this document)) under an offer to existing shareholders on a pre-emptive basis (that is including a rights issue or an open offer), with one-third of the Company's issued share capital being available only in connection with a rights issue (in each case subject to any adjustments, such as for fractional entitlements and overseas shareholders, as the Directors see fit);
- (b) equity securities up to a maximum nominal value of US\$3,650,152 (representing approximately 5% of the issued ordinary share capital of the Company as at February 28, 2019) otherwise than in connection with a pre-emptive offer to existing shareholders on an unrestricted basis.

Resolution 18 is, in line with best practice, proposed as a separate special resolution. If this resolution is passed by shareholders, it will afford the Directors an additional power to allot equity securities on a non-pre-emptive basis and for cash up to a further maximum nominal value of US\$3,650,152, (representing approximately 5% of the issued ordinary share capital of the Company as at February 28, 2019). The Directors shall use any power conferred by Resolution 18 only in connection with an acquisition or a specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding six-month period and is disclosed in the announcement of the issue. The disapplication powers sought in Resolutions 17 and 18 are in line with the Pre-emption Group's Statement of Principles (March 2015) (the 'Pre-emption Principles'). The Pre-emption Principles allow the annual disapplication of pre-emption rights to include 5% of issued ordinary share capital to be issued on an unrestricted basis and an additional 5% of

issued ordinary share capital to be used for “an acquisition or specified capital investment”.

The Board also confirms, in accordance with the Pre-emption Principles, that it does not intend to issue shares for cash representing more than 7.5% of the Company’s issued ordinary share capital in any rolling three-year period other than to existing shareholders, save as permitted in connection with an acquisition or specified capital investment as described above, without prior consultation with shareholders.

These powers will expire on the earlier of the close of business on June 30, 2020 and the conclusion of the Company’s AGM in 2020.

Resolution 19 – Authority to purchase own shares

Resolution 19 will authorize the Directors to make market purchases of the Company’s own ordinary shares pursuant to sections 693 and 701 of the Companies Act 2006. The authority limits the number of ordinary shares that could be purchased up to a maximum of 73,003,058 ordinary shares (equivalent to approximately 10% of the Company’s issued ordinary share capital as at February 28, 2019, being the latest practicable date prior to publication of this document) and sets a minimum and maximum price for such market purchases. This authority will expire on the earlier of the close of business on June 30, 2020 and the conclusion of the Company’s AGM in 2020.

The Company may consider holding any of its own ordinary shares which it purchases pursuant to the authority conferred by this resolution as Treasury shares. This would allow the Company to sell ordinary shares out of Treasury. No dividends will be paid on any ordinary shares held in Treasury and no voting rights will attach to such shares. It will also be possible for the Company to transfer shares out of Treasury pursuant to an employees’ share scheme. As at the latest practicable date prior to publication of this document, the Company held no ordinary shares in Treasury.

As at February 28, 2019 (the latest practicable date prior to the publication of this document), there were 14,056,760 awards and options to subscribe for ordinary shares in the capital of the Company representing 1.92% of the Company’s issued share capital. If the authority to purchase the Company’s ordinary shares being sought in Resolution 19 were to be exercised in full, these awards and options would represent 2.14% of the Company’s issued share capital.

The Directors have no present intention of exercising the authority to purchase the Company’s ordinary shares but will keep the matter under review. The Directors will only exercise this authority when it serves the best interests of the Company and of its shareholders generally and could be expected to result in an increase in the earnings per share of the Company. Any purchases of ordinary shares would be market purchases through the London Stock Exchange.

Resolution 20 – Notice of general meetings

Resolution 20 is a special resolution to allow the Company to hold general meetings, other than AGMs, on not less than 14 clear days’ notice.

Under the Companies Act 2006 the minimum notice period for listed company general meetings is 21 clear days unless (i) shareholders approve a shorter notice period, which cannot be less than 14 clear days and (ii) the Company offers the facility for all shareholders to vote by electronic means. The current authority will expire at the Company’s AGM in 2019 and the Company would like to renew this authority. The Board is therefore proposing Resolution 20 as a special resolution to approve 14 clear days as the minimum period of notice for all general meetings of the Company other than AGMs. The approval will be effective until the Company’s next AGM in 2020. The shorter notice period would not be routinely used. The Board will consider on a case by case basis whether the use of the flexibility offered by the shorter notice period is merited, taking into account the circumstances, including whether the business of the meeting is time-sensitive and whether it is thought to be to the advantage of shareholders as a whole.

Entitlement to attend and vote

1. Entitlement to attend and vote at the meeting, and the number of votes which may be cast at the meeting, will be determined by reference to the Company's register of members at close of business on May 3, 2019 or, if the meeting is adjourned, close of business on the day which is two working days before the day of the adjourned meeting (as the case may be). In each case, changes to the register of members after such time will be disregarded.

Attendance

2. To facilitate entry to the meeting, members are requested to bring with them the attendance slip which is attached to the Form of Proxy. Alternatively, an attendance slip may be downloaded from www.investorcentre.co.uk/eproxy. Registration shall be open from 10.00am at the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London EC1Y 4AG.

Total voting rights

3. Holders of ordinary shares are entitled to attend and vote at general meetings of the Company. Each ordinary share confers one vote on a poll. The total number of issued ordinary shares in the Company on February 28, 2019, which is the latest practicable date before the publication of this document, were 730,030,588. Therefore, the total number of votes exercisable as at February 28, 2019 were 730,030,588.
4. The Company's website will include information on the number of shares and voting rights.

Proxies

5. If you are a member of the Company at the time set out in Note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend and to speak and vote at the meeting. You can only appoint a proxy using the procedures set out in these notes and the notes to the Form of Proxy which is enclosed with this Notice. If you are a Nominated Person, please see Note 17 below.
6. A proxy need not be a shareholder of the Company, but the proxy must attend the AGM to represent you. Your proxy could be the Chair or any other person who has agreed to represent you. Details of how to appoint the Chair of the Meeting or another person as your proxy are set out in the notes to the Form of Proxy. If you wish your proxy to speak on your behalf at the AGM you will need to appoint your own choice of proxy (not the Chair) and give your instructions directly to them.
7. The appointment of a proxy will not prevent a member from subsequently attending and voting at the meeting in person.
8. In the case of joint holders, any one holder may vote. If more than one holder is present at the meeting, only the vote of the senior will be accepted, seniority being determined in the order in which the names appear on the register.
9. A shareholder may appoint more than one proxy in relation to the meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. You may not appoint more than one proxy to exercise rights attached to any one share. A space has been included in the Form of Proxy to allow members to specify the number of

shares in respect of which that proxy is appointed. Shareholders who return the Form of Proxy duly executed but leave this space blank will be deemed to have appointed the proxy in respect of all of their shares.

Shareholders who wish to appoint more than one proxy in respect of their shareholding should contact the Company's Registrars, Computershare Investor Services PLC, on +44 (0) 370 707 1820 for additional Forms of Proxy, or you may photocopy the Form of Proxy provided with this document indicating on each copy the name of the proxy you wish to appoint and the number of ordinary shares in the Company in respect of which the proxy is appointed. All Forms of Proxy should be returned together in the same envelope. Where you wish to appoint more than one proxy, failure to specify the number of ordinary shares in the Company in respect of which each proxy is appointed or specifying more ordinary shares than you hold will result in the proxy appointments being invalid.

10. The notes on the Form of Proxy explain how to direct your proxy on how to vote on the resolution or withhold their vote. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or withhold the vote at his or her discretion. Your proxy will vote (or withhold the vote) as he or she thinks fit in relation to any other matter which is put before the AGM.
11. To appoint a proxy either:
 - (a) the Form of Proxy, and any power of attorney or other authority under which it is executed (or a duly certified copy of any such power or authority), must be completed and deposited with the Company's Registrars, Computershare Investor Services PLC at The Pavilions, Bridgwater Road, Bristol, BS99 6ZY, UK; in the case of a member which is a company, the proxy form should either be sealed by that company or signed by someone authorized to sign it; or
 - (b) your proxy appointment must be lodged online at www.investorcentre.co.uk/eproxy, using the unique shareholder Reference Number (SRN) and Personal Identification Number (PIN), together with the identifying meeting Control Number printed on your proxy card, as referred to in Note 12 below; or
 - (c) the proxy appointment must be lodged using the CREST Proxy Voting Service in accordance with Note 13 below,

in each case so as to be received by no later than 11.00am on Friday May 3, 2019 or, if the meeting is adjourned, by no later than 48 hours (excluding any part of a day that is not a working day) before the time of the holding of the adjourned meeting.

12. Computershare's eProxy service, also known as Electronic Proxy Appointment, is a fast and secure online system for lodging proxy instructions. It offers shareholders an efficient alternative to returning a paper proxy form. In order to lodge a proxy instruction electronically, shareholders should access www.investorcentre.co.uk/eproxy.

For security purposes, shareholders will need to provide their control number, SRN and PIN to validate the submission of their proxy online. The control number, SRN

and PIN numbers are shown on the printed proxy form. If lodging a proxy instruction electronically, there is no need to return the hard-copy Form of Proxy to Computershare.

CREST proxy instructions

13. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the meeting (and any adjournment of the meeting) by following the procedures described in the CREST Manual (available via www.euroclear.com). CREST Personal Members or other CREST sponsored members (and those CREST members who have appointed a voting service provider) should refer to their CREST sponsor or voting service provider, who will be able to take the appropriate action on their behalf.

14. In order for a proxy appointment or instruction made by means of CREST to be valid, the appropriate CREST message (a 'CREST Proxy Instruction') must be properly authenticated in accordance with Euroclear UK & Ireland Limited's (EUI) specifications and must contain the information required for such instructions, as described in the CREST Manual. The message (regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy) must, in order to be valid, be transmitted so as to be received by the issuer's agent (ID 3RA50) by the latest time(s) for receipt of proxy appointments specified in Note 11 above.

For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

After this time any change of instructions to a proxy appointed through CREST should be communicated to him by other means.

15. CREST members (and, where applicable, their CREST sponsors or voting service providers) should note that EUI does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members (and, where applicable, their CREST sponsors or voting service providers) are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

16. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

Shareholders may change proxy instructions by submitting a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions; any amended proxy appointments received after the relevant cut-off time will be disregarded.

Where you have appointed a proxy using the hard-copy proxy form and would like to change the instructions using another hard-copy proxy form, please contact Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ, UK.

If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

A shareholder may change a proxy instruction but to do so you will need to inform the Company in writing by sending a signed hard-copy notice clearly stating your intention to revoke your proxy appointment to Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS99 6ZY, UK. In the case of a shareholder which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice.

The revocation notice must be received by Computershare Investor Services PLC by no later than 11.00am on Friday May 3, 2019 or, if the meeting is adjourned, by no later than 48 hours (excluding any part of a day that is not a working day) before the time of the holding of the adjourned meeting. If you attempt to revoke your proxy appointment but the revocation is received after the time specified, your original proxy appointment will remain valid unless you attend the meeting and vote in person.

Nominated persons

17. The right to appoint a proxy does not apply to persons whose shares are held on their behalf by another person and who have been nominated to receive communications from the Company in accordance with Section 146 of the Companies Act 2006 ('Nominated Persons'). Nominated Persons may have a right under an agreement with the member who holds the shares on their behalf to be appointed (or to have someone else appointed) as a proxy.

Alternatively, if Nominated Persons do not have such a right, or do not wish to exercise it, they may have a right under such an agreement to give instructions to the person holding the shares as to the exercise of voting rights. The main point of contact in terms of the investment of Nominated Persons in the Company remains the member who holds shares on their behalf (or perhaps the custodian or broker of the Nominated Person). All queries relating to the personal details or investment of Nominated Persons should be directed to the relevant member and not the Company. The only exception is where the Company expressly requests a response to communications from a Nominated Person.

Corporate representative

18. A corporation which is a shareholder can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same share.

Automatic poll voting

19. Resolutions 1 to 20 will be put to the meeting and will be voted on by poll. For the purposes of the Company's articles of association, the Chair of the meeting has demanded these resolutions be voted on by poll. A poll reflects the number of voting rights exercisable by each member and so the Board considers it a more democratic method of voting. Poll voting is in line with practice increasingly adopted by UK public companies. Members and proxies will be asked to complete a poll card to indicate how they wish to cast their votes. These cards will be collected at the end of the meeting. The results of the poll will be published on the Company's website and announced via a Regulatory Information Service once the votes have been counted and verified.

Questions

20. Any member attending the meeting has the right to ask questions. The Company must cause to be answered any such question relating to the business being dealt with at the meeting but no such answer need be given if (a) to do so would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information, (b) the answer has already been given on a website in the form of an answer to a question, or (c) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.

Members' rights

21. Members satisfying the thresholds in section 527 of the Companies Act 2006 can require the Company to publish a statement on a website setting out any matter relating to (a) the audit of the Company's accounts (including the Auditor's report and the conduct of the audit) that are to be laid before the meeting; or (b) any circumstances connected with an Auditor of the Company ceasing to hold office since the last AGM, that the members propose to raise at the meeting. The Company cannot require the members requesting the publication to pay its expenses in complying with sections 527 or 528 of the Companies Act 2006. Any statement placed on the website must also be sent to the Company's Auditor no later than the time the Company makes its statement available on the website. The business which may be dealt with at the meeting includes any such statement that the Company has been required to publish on a website.
22. Under sections 338 and 338A of the Companies Act 2006, members meeting the threshold requirements in those sections have the right to require the Company: (i) to give, to members of the Company entitled to receive notice of the meeting, notice of a resolution which those members intend to move (and which may properly be moved) at the meeting; and; (ii) to include in the business to be dealt with at the meeting any matter (other than a proposed resolution) which may properly be included in the business at the meeting. A resolution may properly be moved, or a matter properly included in the business, unless (a) (in the case of a resolution only) it would, if passed, be ineffective (whether by reason of any inconsistency with any enactment or the Company's constitution or otherwise); (b) it is defamatory of any person; or (c) it is frivolous or vexatious.

A request made pursuant to this right may be in hard copy or electronic form, must identify the resolution of which notice is to be given or the matter to be included in the business, must be authenticated by the person(s) making it and must be received by the Company not later than March 14, 2019 being the date of this notice of meeting, and (in the case of a matter to be included in the business only) must be accompanied by a statement setting out the grounds for the request.

Conduct of the meeting

23. We ask all those present at the meeting to facilitate the orderly conduct of the meeting and reserve the right, if orderly conduct is threatened by a person's behavior, to require that person to leave. For security reasons, all hand luggage may be subject to examination prior to entry to the meeting. Cameras, tape recorders, laptop computers and similar equipment may not be taken into the meeting.

Additional information

24. A copy of this notice and other information required by Section 311A of the Companies Act 2006 can be found at www.indivior.com.
25. Copies of the Directors' service contracts with the Company and the terms and conditions of the Non-Executive Directors' appointment are available for inspection at the registered office of the Company at any time during normal business hours on weekdays, (Saturdays, Sundays and public holidays excepted) up to and including the day of the AGM and at the venue for the AGM from 10.45am on May 8, 2019 until the conclusion of the AGM. All references to times in this notice are to UK time.

Communication

26. Except as provided above, members who have general queries about the AGM should use the following means of communication (no other methods of communication will be accepted):
- (a) by calling our shareholder helpline on +44 (0) 370 707 1820; or
 - (b) in writing to Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ; or
 - (c) online at www.investorcentre.co.uk
- You may not use any electronic address provided either in this Notice of Meeting; or any related documents (including the proxy form), to communicate with the Company for any purposes other than those expressly stated.